Compare GSK plc (GSK) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Illinois Tool Works Inc. — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Illinois Tool Works Inc. trades at $263.78 (market cap $74.38B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Illinois Tool Works Inc. for 67 Days on average.
| GSK | ITW | |
|---|---|---|
Market Cap | $91.88B | $74.38B |
Volume | 7,730,529 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $61.18 | $299.60 |
52-Week Low | $43.24 | $241.07 |
Typical Hold Time | 93 Days | 67 Days |
Enterprise Value | $111.88B | $83.23B |
Dividend Yield | 3.9% | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
ITW trades at $264.42, up 1.25% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 19.39% net margins and 104.65% ROE. Recent dividend increase to $1.72 reinforces its 59-year dividend growth streak. Revenue stability around $16B and operational cash flow exceeding $3B demonstrate business resilience despite mixed analyst sentiment.
Outlook remains balanced with upside to $276.86 consensus target but technical weakness near-term. Key opportunities include dividend reliability and margin strength, while risks involve debt levels at 55.54% of assets and sector cyclicality. The stock offers quality exposure for dividend-growth investors despite current technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
